Roivant Sciences (NASDAQ:ROIV) Given “Buy” Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Roivant Sciences (NASDAQ:ROIV) in a research note issued to investors on Monday morning, Benzinga reports. HC Wainwright currently has a $18.00 target price on the stock.

Several other equities analysts also recently issued reports on ROIV. Wolfe Research started coverage on shares of Roivant Sciences in a report on Thursday, February 15th. They set an outperform rating and a $17.00 price target for the company. Bank of America boosted their target price on Roivant Sciences from $11.00 to $12.00 and gave the stock a neutral rating in a report on Tuesday, January 2nd. Truist Financial reiterated a buy rating and issued a $23.00 price objective on shares of Roivant Sciences in a research report on Monday, March 25th. Piper Sandler began coverage on Roivant Sciences in a research note on Friday, January 5th. They issued an overweight rating and a $20.00 price objective on the stock. Finally, Deutsche Bank Aktiengesellschaft raised their target price on Roivant Sciences from $14.00 to $15.00 and gave the company a buy rating in a research note on Wednesday, April 3rd. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat.com, Roivant Sciences presently has an average rating of Moderate Buy and an average target price of $16.90.

Roivant Sciences Stock Up 1.3 %

ROIV opened at $10.60 on Monday. The company has a market capitalization of $8.54 billion, a P/E ratio of 2.08 and a beta of 1.34. The company has a debt-to-equity ratio of 0.06, a current ratio of 27.79 and a quick ratio of 27.79. The firm’s fifty day moving average price is $10.95 and its two-hundred day moving average price is $10.36. Roivant Sciences has a fifty-two week low of $8.06 and a fifty-two week high of $13.24.

Roivant Sciences (NASDAQ:ROIV) last released its quarterly earnings data on Tuesday, February 13th. The company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.07. The company had revenue of $37.14 million during the quarter, compared to the consensus estimate of $30.72 million. Roivant Sciences had a net margin of 3,624.14% and a negative return on equity of 33.38%. On average, analysts anticipate that Roivant Sciences will post -1.36 EPS for the current year.

Insider Activity

In related news, COO Eric Venker sold 96,950 shares of Roivant Sciences stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $10.92, for a total value of $1,058,694.00. Following the completion of the sale, the chief operating officer now directly owns 532,207 shares in the company, valued at $5,811,700.44. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 4.60% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Roivant Sciences

Hedge funds and other institutional investors have recently bought and sold shares of the business. State of Alaska Department of Revenue acquired a new position in shares of Roivant Sciences in the 1st quarter valued at $389,000. State of Michigan Retirement System bought a new position in Roivant Sciences during the first quarter worth about $853,000. Allspring Global Investments Holdings LLC grew its position in shares of Roivant Sciences by 1,207.5% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 70,410 shares of the company’s stock worth $742,000 after buying an additional 65,025 shares during the period. Beryl Capital Management LLC bought a new stake in shares of Roivant Sciences in the 4th quarter valued at about $2,808,000. Finally, Altitude Crest Partners Inc. acquired a new stake in shares of Roivant Sciences in the 4th quarter valued at approximately $9,075,000. 64.76% of the stock is owned by institutional investors.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.